INDEMNITY AGREEMENTIndemnification Agreement • January 15th, 2021 • Lucira Health, Inc. • In vitro & in vivo diagnostic substances • Delaware
THIS INDEMNITY AGREEMENT (this “Agreement”) dated as of ____________, is made by and between LUCRIA HEALTH, INC., a Delaware corporation (the “Company” or “Lucira” ), and ____________ (“Indemnitee” ).
LUCIRA HEALTH, INC.Employment Agreement • January 15th, 2021 • Lucira Health, Inc. • In vitro & in vivo diagnostic substances • California
You are currently employed by LUCIRA HEALTH, INC. (the “Company”) under the terms of an offer letter between you and the Company dated August 10, 2013 (the “Offer Letter”). The Company is amending and restating the terms of the Offer Letter to reflect your new employment terms as set forth in this employment agreement (the “Agreement”). Once you accept this Agreement by signing and returning it to the Company, this Agreement shall supersede and replace your Offer Letter in its entirety, and this Agreement shall then govern the terms of your employment with the Company.
OFFICE LEASE ARTICLE 1 BASIC LEASE PROVISIONSLease • January 15th, 2021 • Lucira Health, Inc. • In vitro & in vivo diagnostic substances • California
PATENT LICENSE AGREEMENTPatent License Agreement • January 15th, 2021 • Lucira Health, Inc. • In vitro & in vivo diagnostic substances
THIS PATENT LICENSE AGREEMENT (this “Agreement”), dated as of this 15th day of July, 2020 (the “Effective Date”), by and between Eiken Chemical Co., Ltd., a corporation organized and existing under the laws of Japan with its principal place of business at 19-9, Taito 4-chome, Taito-ku, Tokyo, Japan (“Eiken”) and Lucira Health, Inc., a corporation organized and existing under the laws of Delaware with its principal place of business at 1412 62nd Street, Emeryville, CA 94608 U.S.A. (“Lucira”).
MANUFACTURING SERVICES AGREEMENT between JABIL INC., and LUCIRA HEALTH INC.Manufacturing Services Agreement • January 15th, 2021 • Lucira Health, Inc. • In vitro & in vivo diagnostic substances • Delaware
This Manufacturing Service Agreement (“Agreement”) is entered into as of September 10th, 2020 (“Effective Date”) by and between Jabil Inc., having its principal place of business at 10560 Dr. M.L. King Jr. Street North St. Petersburg, Florida 33716, on behalf of itself and its affiliates (“Jabil”), and Lucira Health, Inc. a Delaware corporation, (“Company”). Jabil and Company are referred to herein individually as “Party”, or collectively as “Parties”.
LUCIRA HEALTH, INC. AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • January 15th, 2021 • Lucira Health, Inc. • In vitro & in vivo diagnostic substances • Delaware
THIS AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (this “Agreement”), is made as of the 7th day of August, 2020, by and among Lucira Health, Inc., a Delaware corporation (the “Company”), each of the investors listed on SCHEDULE A hereto, each of which is referred to in this Agreement as an “Investor”, and any Additional Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with Section 6.9 hereof.
